Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P05106

UPID:
ITB3_HUMAN

ALTERNATIVE NAMES:
Platelet membrane glycoprotein IIIa

ALTERNATIVE UPACC:
P05106; A0PJW2; D3DXJ8; O15495; Q12806; Q13413; Q14648; Q16499

BACKGROUND:
The protein Integrin beta-3, known for its alternative name Platelet membrane glycoprotein IIIa, is a receptor critical for cell adhesion, playing a key role in various physiological processes. It interacts with numerous ligands, including osteopontin and vitronectin, facilitating cell-matrix interactions essential for tissue repair and immune response. Its recognition of specific ligand sequences is crucial for cellular signaling and adhesion mechanisms.

THERAPEUTIC SIGNIFICANCE:
Given Integrin beta-3's crucial role in diseases like Glanzmann thrombasthenia and macrothrombocytopenia, its study could lead to novel therapeutic strategies. Understanding the role of Integrin beta-3 could open doors to potential therapeutic strategies, particularly in developing treatments that target the underlying mechanisms of these platelet disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.